Edwards Lifesciences is a global leader in innovative medical technology, specializing in heart valve repair and replacement, as well as critical care monitoring
The company focuses on developing advanced products to enhance the quality of heart surgery and improve patient outcomes. Edwards Lifesciences is dedicated to addressing cardiovascular disease, which remains a leading cause of death worldwide, by providing solutions that enable less invasive procedures and better management of patients with heart-related conditions. Through continuous research and development, the company strives to transform patient care in the fields of heart disease and surgical intervention.
Edwards Lifesciences Corporation (NYSEEW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company projects continued expansion in 2025.
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New York.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSEEW).
Edwards Lifesciences (NYSEEW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSEEW).
What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Jan. 13-17, 2025.
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Edwards Lifesciences Corp (NYSEEW) on behalf of long-term stockholders following a class action complaint that was filed against Edwards on October 14, 2024 with a Class Period from February 6, 2024 to July 24, 2024. Our investigation concerns whether the board of directors of Edwards have breached their fiduciary duties to the company.
